Search

Background: The evolving opinions of our community members provide insights into how end-users perceive the value and identify key point-of-care test (POCT) characteristics. Methods: We deployed our validated 45-item English-language survey to uncompensated volunteers and compared the results from 1264 respondents in 2021 with those obtained in 2020. Results: Average responses for items regarding the benefits of POCTs demonstrated that the 2021 respondents indicated agreement with all 14 potential benefits. Average responses for items regarding concerns were distinctly different from those for benefits. The only concern item that scored in the agree range was "not having insurance coverage for POCTs." Average responses to the other 13 concern items were in the disagree range. For 8 of these items, the magnitude of disagreement was greater in the 2021 survey than was observed for the 2020 survey. Differences in POCT exposure over time and by US regions suggest that higher levels of exposure to POCTs in the East are associated with stronger public support. Conclusions: Community members strongly support the development of accurate, convenient, easy-to-use, affordable, equitably available, in-home POCTs that produce immediate results. This empowers patients and home caregivers to diagnose, manage, enhance their adherence to medical treatments, and more efficiently engage their physicians. [ABSTRACT FROM AUTHOR]

Background: The evolving opinions of our community members provide insights into how end-users perceive the value and identify key point-of-care test (POCT) characteristics., Methods: We deployed our validated 45-item English-language survey to uncompensated volunteers and compared the results from 1264 respondents in 2021 with those obtained in 2020., Results: Average responses for items regarding the benefits of POCTs demonstrated that the 2021 respondents indicated agreement with all 14 potential benefits. Average responses for items regarding concerns were distinctly different from those for benefits. The only concern item that scored in the agree range was "not having insurance coverage for POCTs." Average responses to the other 13 concern items were in the disagree range. For 8 of these items, the magnitude of disagreement was greater in the 2021 survey than was observed for the 2020 survey. Differences in POCT exposure over time and by US regions suggest that higher levels of exposure to POCTs in the East are associated with stronger public support., Conclusions: Community members strongly support the development of accurate, convenient, easy-to-use, affordable, equitably available, in-home POCTs that produce immediate results. This empowers patients and home caregivers to diagnose, manage, enhance their adherence to medical treatments, and more efficiently engage their physicians., Competing Interests: Authors’ Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest: Employment or Leadership: D. McManus, American Heart Association. Consultant or Advisory Role: J. Kaye, Eli Lilly DSMB, Sage Bionetworks Scientific Advisory Board, Stanford University Alzheimer’s Disease Research Center External Advisory Committee, Rush University Alzheimer’s Disease Research Center External Advisory Committee; D. McManus, consulting fees from Bristol Myers Squibb, Pfizer, Fitbit, Avania, Flexcon, Heart Rhythm Society and Data Safety Monitoring Board or Advisory Board for Avania Consulting, Fitbit, Bristol Myers Squibb. Stock Ownership: J. Kaye, Life Analytics Inc. Honoraria: J. Kaye, Aging & Health Informatics Conference Presentation—Sponsored by University of Texas, Austin; D. McManus, Heart Rhythm Society. Research Funding: C.M. Lilly, Z. Wang, D. Dunlap, N. Hafer, B. Buchholz, and D. McManus received grant support for this project from National Institutes of Health Grant U54-HL 143541. J. Kaye received financial support from Eli Lilly, Sage Bionetworks, OHSU Alzheimer’s Disease Research Center, Stanford Alzheimer’s Disease Research Center, Rush University Alzheimer’s Disease Research Center, DETECT AD (R56AG074321), Life Analytics, and the Oregon Center for Aging & Technology. D. McManus received financial support from Bristol Meyers Squibb, Pfizer, Fitbit, Avania, Heart Rhythm Society, Flexcon, Boehringer Ingelheim and Philips, Samsung, Apple, and Rose Consulting. Expert Testimony: None declared. Patents: None declared. Other Remuneration: D. McManus, personal fees from Bristol Meyers Squibb, Pfizer, Samsung, Flexcon, Avania, Rose Consulting, Heart Rhythm Society, Fitbit and nonfinancial support from Apple, Samsung, Fitbit., (© American Association for Clinical Chemistry 2022. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)